{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:51:14Z","timestamp":1781805074900,"version":"3.54.5"},"reference-count":39,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W003988\/1"],"award-info":[{"award-number":["MR\/W003988\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) reduce heart failure (HF) risk in type 2 diabetes (T2D) and are recommended for patients with T2D who have atherosclerotic cardiovascular disease (ASCVD), HF, or chronic kidney disease (CKD). However, most individuals with T2D do not have these conditions, and current guidelines for this group do not indicate which individuals may benefit most from SGLT2i. We aimed to develop and validate a model to predict the individual-level HF benefit of SGLT2i in individuals with T2D without ASCVD, HF, or CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>We developed the SGLT2i Absolute Benefit Response (SABRE) model, combining absolute HF risk from the validated QDiabetes-HF model with the SGLT2i-associated hazard ratio (HR) for HF hospitalization from a trial meta-analysis (HR 0.63) to estimate individual 5-year HF benefit. Model components and predictions were validated using U.K. primary care data with linked hospital and death records from 2013 to 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 57,368 SGLT2i initiators and 111,673 comparator (dipeptidyl peptidase 4 inhibitor or sulfonylurea) initiators, SGLT2i use was associated with a 30% lower risk of new-onset HF (HR 0.70 [95% CI 0.63\u20130.78]), consistent with trial evidence. Relative HF benefit did not vary by baseline absolute HF risk (P = 0.82). The SABRE model\u2013predicted 5-year absolute HF benefit with SGLT2i ranged from &amp;lt;0.1% to 14.1% (median 1.0% [interquartile range 0.6\u20131.8%]) and calibrated well against observed HF outcomes. SABRE provided more targeted HF prevention than current guidelines in those with T2D without ASCVD, HF, or CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The SABRE model is an easily deployed clinical prediction model integrating trial evidence and allowing more precise targeting of SGLT2i for primary HF prevention in T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-2973","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:02:32Z","timestamp":1779303752000},"page":"1115-1123","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-3864","authenticated-orcid":false,"given":"Katherine G.","family":"Young","sequence":"first","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6833-9399","authenticated-orcid":false,"given":"Andrew P.","family":"McGovern","sequence":"additional","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-3582","authenticated-orcid":false,"given":"Rhian","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5686-5033","authenticated-orcid":false,"given":"Thijs T.","family":"Jansz","sequence":"additional","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-874X","authenticated-orcid":false,"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford 2 , Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-8585","authenticated-orcid":false,"given":"Ewan R.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Reproductive Medicine, Ninewells Hospital and Medical School, University of Dundee 3 , Dundee, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-473X","authenticated-orcid":false,"given":"Andrew T.","family":"Hattersley","sequence":"additional","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0883-7599","authenticated-orcid":false,"given":"Angus G.","family":"Jones","sequence":"additional","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Docherty","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow 4 , Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow 4 , Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-327X","authenticated-orcid":false,"given":"Beverley M.","family":"Shields","sequence":"additional","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-732X","authenticated-orcid":false,"given":"John M.","family":"Dennis","sequence":"additional","affiliation":[{"name":"Clinical and Biomedical Sciences, University of Exeter Medical School 1 , Exeter, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MASTERMIND Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026061812560953200_B1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026061812560953200_B2","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2026061812560953200_B3","article-title":"Type 2 diabetes in adults: management","author":"National Institute for Health and Care Excellence"},{"key":"2026061812560953200_B4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12933-023-02032-x","article-title":"Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy","volume":"22","author":"Young","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026061812560953200_B5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement","volume":"172","author":"Kent","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026061812560953200_B6","doi-asserted-by":"crossref","first-page":"e008503","DOI":"10.1136\/bmjopen-2015-008503","article-title":"Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study","volume":"5","author":"Hippisley-Cox","year":"2015","journal-title":"BMJ Open"},{"key":"2026061812560953200_B7","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2026061812560953200_B8","article-title":"Release Notes: CPRD Aurum October 2020","author":"Medicines and Healthcare Products Regulatory Agency"},{"key":"2026061812560953200_B9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061812560953200_B10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026061812560953200_B11","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies","volume":"352","author":"Li","year":"2016","journal-title":"BMJ"},{"key":"2026061812560953200_B12","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur Heart J"},{"key":"2026061812560953200_B13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2026061812560953200_B14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2026061812560953200_B15","doi-asserted-by":"crossref","first-page":"e008503","DOI":"10.1136\/bmjopen-2015-008503","article-title":"Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study","volume":"5","author":"Hippisley-Cox","year":"2015","journal-title":"BMJ Open"},{"key":"2026061812560953200_B16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J Amer Stat Assoc"},{"key":"2026061812560953200_B17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061812560953200_B18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"key":"2026061812560953200_B19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2020.12.008","article-title":"Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial","volume":"233","author":"Sarraju","year":"2021","journal-title":"Am Heart J"},{"key":"2026061812560953200_B20","doi-asserted-by":"crossref","unstructured":"Neal\n              B\n            , PerkovicV, MahaffeyKW, . Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med2017;377:644\u2013657","DOI":"10.1056\/NEJMoa1611925"},{"key":"2026061812560953200_B21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"2026061812560953200_B22","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"key":"2026061812560953200_B23","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061812560953200_B24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026061812560953200_B25","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41591-024-03033-3","article-title":"Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist","volume":"30","author":"Lim","year":"2024","journal-title":"Nat Med"},{"key":"2026061812560953200_B26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061812560953200_B27","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"2026061812560953200_B28","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.122.063374","article-title":"Twenty years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study","volume":"147","author":"Sattar","year":"2023","journal-title":"Circulation"},{"key":"2026061812560953200_B29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/dom.14893","article-title":"Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies","volume":"25","author":"Hinton","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026061812560953200_B30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s43856-023-00359-w","article-title":"Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review","volume":"3","author":"Young","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"2026061812560953200_B31","article-title":"Heart Failure: Causes and Risk Factors","author":"National Heart, Lung, and Blood Institute"},{"key":"2026061812560953200_B32","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.2337\/dc25-1260","article-title":"Screening natriuretic peptide levels predicts heart failure and death in individuals with type 1 and type 2 diabetes without known heart failure","volume":"48","author":"Pop-Busui","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061812560953200_B33","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.2337\/dc21-1929","article-title":"Clinical utility of cardiovascular risk scores for identification of people with type 2 diabetes more likely to benefit from either GLP-1 receptor agonist or SGLT2 inhibitor therapy","volume":"45","author":"Sacre","year":"2022","journal-title":"Diabetes Care"},{"key":"2026061812560953200_B34","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00125-024-06190-9","article-title":"Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach","volume":"67","author":"G\u00fcdemann","year":"2024","journal-title":"Diabetologia"},{"key":"2026061812560953200_B35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(24)02617-5","article-title":"A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study","volume":"405","author":"Dennis","year":"2025","journal-title":"Lancet"},{"key":"2026061812560953200_B36","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00125-025-06577-2","article-title":"Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection","volume":"69","author":"Jansz","year":"2026","journal-title":"Diabetologia"},{"key":"2026061812560953200_B37","doi-asserted-by":"crossref","first-page":"108831","DOI":"10.1016\/j.diabres.2021.108831","article-title":"The impact of diabetes on heart failure development: the cardio-renal-metabolic connection","volume":"175","author":"Valensi","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061812560953200_B38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061812560953200_B39","doi-asserted-by":"crossref","first-page":"e019463","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/6\/1115\/870397\/dc252973.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/6\/1115\/870397\/dc252973.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:56:17Z","timestamp":1781801777000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/6\/1115\/166973\/Precision-Prescribing-of-SGLT2-Inhibitors-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,20]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-2973","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}